Resistance mechanisms and clonal dynamics in mantle cell lymphoma treated with sequential BTKi and venetoclax therapy
The Journal of Pathology · 2025-08 · 266 (4-5) · 395-404
DOI: 10.1002/path.6434 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Pathology, online erschienen am 15.05.2025. Verfasst von Tamás László und 19 weiteren Autor:innen. Beteiligte Einrichtung: HCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Drug Resistance, Neoplasm, Sulfonamides, Bridged Bicyclo Compounds, Heterocyclic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Research, Development and Innovation Fund, Lendület Program of the Hungarian Academy of Sciences, János Bolyai Research Scholarship program of the Hungarian Academy of Sciences.
Abstract (Originalsprache)
In recent years, targeted therapies have become the standard of care for refractory/relapsed mantle cell lymphoma (MCL). Although the mutational profile of MCL has been extensively studied, there is a lack of understanding of resistance mechanisms and genetic factors that impact the response to novel treatments. Since patients relapsing on targeted treatment experience poor clinical outcomes, understanding the genetic foundation of resistance mechanisms in MCL is essential. In this study, we aimed to scrutinize the copy number profile and clonal dynamics of double‐resistant MCL patients treated sequentially with Bruton's tyrosine kinase inhibitor (BTKi) and venetoclax using low‐coverage whole genome sequencing (lcWGS). Samples obtained after systemic therapy showed more copy number alterations (CNAs) ( p = 0.039; Wilcoxon) compared to samples collected before treatment initiation. Patients showing early progression on BTKi demonstrated CNAs affecting cytobands encompassing the coding regions of NOTCH1 , TRAF2 , BIRC2 , BIRC3 , and ATM . A deletion in chromosome 9p21.3 was identified in two out of three venetoclax‐resistant patients. For patient MCL2, progressing on ibrutinib but showing venetoclax resistance, a 9p21.3 deletion was found throughout the disease course, with acquired SMARCA4 ‐del(19)(p13.3–q13.11) and DLC1 –del(8)(p23.2–q11.1) observed at relapse, highlighting their role in disease progression and therapy resistance. Using lcWGS, an innovative genome‐wide approach, this study revealed novel putative primary and acquired resistance mechanisms in BTKi and venetoclax double‐resistant MCL patients. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- HCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
- MTA-SE Lendület Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
- Division of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
- Doctoral School of Clinical Medicine, University of Debrecen, Debrecen, Hungary.
- Department of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary.
- Markusovszky University Teaching Hospital, Szombathely, Hungary.
ORCID-Profile: Tamás László, Csaba Bödör
Förderung
- National Research, Development and Innovation Fund
- Lendület Program of the Hungarian Academy of Sciences
- János Bolyai Research Scholarship program of the Hungarian Academy of Sciences
- National Research, Development, and Innovation Office, Hungary
- European Union
- Nemzeti Kutatási, Fejlesztési és Innovaciós Alap
- European Commission
Zitieren
APA
László, T., Pinczés, L. I., Bátai, B., Varga, L., Timár, B., Gulyás, A., Tárkányi, I., Plander, M., Nagy, Z., Rajnics, P., Egyed, M., Molnár, Z., Rottek, J., Masszi, A., Tamáska, P., Szász, R., Illés, Á., Alpár, D., Magyari, F., & Bödör, C. (2025). Resistance mechanisms and clonal dynamics in mantle cell lymphoma treated with sequential BTKi and venetoclax therapy. The Journal of Pathology, 266(4-5), 395-404. https://doi.org/10.1002/path.6434
Vancouver
László T, Pinczés LI, Bátai B, Varga L, Timár B, Gulyás A, et al. Resistance mechanisms and clonal dynamics in mantle cell lymphoma treated with sequential BTKi and venetoclax therapy. The Journal of Pathology. 2025;266(4-5):395-404. doi:10.1002/path.6434
BibTeX
@article{Lszl2025,
author = {László, Tamás and Pinczés, László Imre and Bátai, Bence and Varga, Luca and Timár, Botond and Gulyás, Anita and Tárkányi, Ilona and Plander, Márk and Nagy, Zsolt and Rajnics, Péter and Egyed, Miklós and Molnár, Zsuzsa and Rottek, János and Masszi, András and Tamáska, Péter and Szász, Róbert and Illés, Árpád and Alpár, Donát and Magyari, Ferenc and Bödör, Csaba},
title = {Resistance mechanisms and clonal dynamics in mantle cell lymphoma treated with sequential BTKi and venetoclax therapy},
journal = {The Journal of Pathology},
year = {2025},
volume = {266},
number = {4-5},
pages = {395--404},
doi = {10.1002/path.6434}
}
EUVIMED